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Abstract
Introduction: Osteoclastogenesis plays an important role in the bone erosion of rheumatoid arthritis (RA).
Recently, Notch receptors have been implicated in the development of osteoclasts. However, the responsible
Notch ligands have not been identified yet. This study was undertaken to determine the role of individual Notch
receptors and ligands in osteoclastogenesis.
Methods: Mouse bone marrow-derived macrophages or human peripheral blood monocytes were used as
osteoclast precursors and cultured with receptor activator of nuclear factor-kappaB ligand (RANKL) and
macrophage-colony stimulating factor (M-CSF) to induce osteoclasts. Osteoclasts were detected by tartrate-resistant
acid phosphatase (TRAP) staining. K/BxN serum-induced arthritic mice and ovariectomized mice were treated with
anti-mouse Delta-like 1 (Dll1) blocking monoclonal antibody (mAb).
Results: Blockade of a Notch ligand Dll1 with mAb inhibited osteoclastogenesis and, conversely, immobilized Dll1-
Fc fusion protein enhanced it in both mice and humans. In contrast, blockade of a Notch ligand Jagged1
enhanced osteoclastogenesis and immobilized Jagged1-Fc suppressed it. Enhancement of osteoclastogenesis by
agonistic anti-Notch2 mAb suggested that Dll1 promoted osteoclastogenesis via Notch2, while suppression by
agonistic anti-Notch1 mAb suggested that Jagged1 suppressed osteoclastogenesis via Notch1. Inhibition of Notch
signaling by a gamma-secretase inhibitor suppressed osteoclastogenesis, implying that Notch2/Dll1-mediated
enhancement was dominant. Actually, blockade of Dll1 ameliorated arthritis induced by K/BxN serum transfer,
reduced the number of osteoclasts in the affected joints and suppressed ovariectomy-induced bone loss.
Conclusions: The differential regulation of osteoclastogenesis by Notch2/Dll1 and Notch1/Jagged1 axes may be a
novel target for amelioration of bone erosion in RA patients.
Introduction
Notch signaling pathways play key roles in cell-fate deci-
sion and differentiation in many tissues during embryonic
and postnatal development [1]. Four mammalian Notch
receptors have been identified, designated as Notch1 to
Notch4. Interaction of Notch receptors with membrane-
bound ligands of the Delta and Jagged families (Delta-like1
(Dll1), Dll4, Jagged1, and Jagged2) induces gamma-secre-
tase-mediated cleavage and translocation of Notch intracel-
lular domain (ICD) into the nucleus, where it interacts with
the transcription factor CSL. Once bound to CSL, Notch
intracellular domain recruits other coactivators, including
mastermind proteins, and this transcriptional activation
complex induces the expression of downstream target
genes, such as Hairly Enhancer of Split -1 (Hes-1) [2].
The importance of Notch signaling in osteoclastogen-
esis has recently been reported [3,4]. Osteoclasts are
derived from the monocyte/macrophage lineage and are
responsible for bone resorption [5]. Osteoclast differen-
tiation is a multistep process that leads to expression of
tartrate-resistant acid phosphatase (TRAP), multinuclea-
tion and bone-resorbing activity. It has been demon-
strated that receptor activator of nuclear factor-kappaB
ligand (RANKL) and macrophage-colony stimulating fac-
tor (M-CSF) are critical for osteoclast development [6].
CD51/CD61, TRAP and matrix metalloproteinase-9 are
widely used as specific markers for osteoclasts [7]. Con-
trolling osteoclastogenesis is important for bone homeos-
tasis and an abnormal osteoclastogenesis leads to
imbalance of bone remodeling that is related to various
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diseases such as osteoporosis, rheumatoid arthritis (RA),
and multiple myeloma [5].
RA is a chronic autoimmune disease characterized by
inflammation of synovial joints leading to erosion of
bone and ultimately functional loss of joints. This bone
destruction is caused by enhanced activity of osteoclasts
[8]. In chronic inflammation, pro-osteoclastogenic factors
often predominate, leading to increased osteoclast forma-
tion and pathological bone resorption. Current therapies
to treat RA have focused on inhibition of inflammation
in the joints. To prevent structural destruction of the
joints, it is important to explore the regulation of osteo-
clasts as a new therapeutic approach for the treatment of
RA.
A recent report demonstrated that deletion of Notch1
and/or Notch3 in mouse osteoclast precursor cells pro-
moted osteoclast differentiation and overexpression of a
Notch ligand Jagged1 suppressed osteoclastogenesis, sug-
gesting a suppressive role for Notch/Jagged1 in osteoclas-
togenesis [3]. On the other hand, Notch2 has been shown
to accelerate osteoclastogenesis in association with
nuclear factor-kappaB, and induction of Notch signaling
by Jagged1 promoted osteoclast differentiation [4]. Thus,
possibly differential contributions of individual Notch
receptors and ligands to the regulation of osteoclastogen-
esis remain elusive. In addition, the contribution of
Notch receptors and ligands to human osteoclastogenesis
has not been determined yet.
We have recently established a panel of monoclonal
antibodies (mAbs) specific for mouse Notch receptors
and ligands [9]. In this study, we investigated the effect of
these mAbs on the differentiation of bone marrow (BM)
cells into osteoclasts. We have also newly established
mAbs against human Notch receptors and ligands, and
determined their effects on the osteoclastogenesis from
human peripheral blood monocytes (PBmono). Our
results suggest that Dll1/Notch2 interaction promotes
osteoclastogenesis, whereas Jagged1/Notch1 interaction
suppresses it in both mice and humans. Actually, treat-
ment with anti-mouse Dll1 blocking mAb ameliorated
K/BxN serum-induced arthritis, a mouse model of RA,
and reduced osteoclasts number in the affected joints.
The differential regulation of osteoclastogenesis by the
Dll1/Notcn2 and Jagged1/Notch1 axes may have patholo-
gical and therapeutic relevancies to RA.
Materials and methods
Mice
C57BL/6 mice were purchased from Charles River
(Oriental Yeast, Tokyo, Japan). Dll1 conditional knock-
out mice were generated as described previously [10].
For inducible deletion of Dll1, four-week-old Dll1lox/lox
Mx-Cre+ or littermate control Dll1lox/lox Mx-Cre- mice
were injected with 0.3 mg of poly(I):(C) twice a week for
two weeks, and used three weeks later. All animal
experiments were approved by Juntendo University Ani-
mal Experimental Ethics Committee.
Reagents
The gamma-secretase inhibitor DAPT (N-[N-(3,5-
difluorophenacetyl-L- alanyl)]-S-phenylglysin t-butyl
ester), was purchased from Calbiochem (San Diego, CA,
USA). The mouse Jagged1-Fc and mouse Dll1-Fc fusion
proteins were generated as previously described [11]. The
mouse Jagged2-Fc and human Jagged1-Fc fusion proteins
were purchased from R&D Systems (Minneapolis, MN,
USA). The human Dll1-Fc fusion protein was purchased
from Alexis Biochemicals (Lausen, Switzerland). The
human IgG Fc fragment was purchased from Acris Anti-
bodies (Herford, Germany). Mouse Fc Block (2.4G2; BD
Bioscience, San Jose, CA, USA) and Functional Grade
Purified Human Fc(gamma)R-Binding Inhibitor
(eBioscience, San Diego, CA, USA) were used to block
non-specific binding of mAbs to Fc(gamma) receptors.
Generation of mAbs
To generate the mAbs specific for human Dll1, Dll4,
Jagged1 and Jagged2, Balb/c mice (Charles River) were
immunized by intraperitoneal injection of human Dll1-
Fc or Jagged1-Fc fusion protein, recombinant human
Dll4 (R&D Systems), or Jagged2-transfected CHO cells
three times at seven-day intervals. Three days after the
final immunization, the splenocytes were fused with
P3U1 myeloma cells. After hypoxanthine aminopterin
thymidine (HAT) selection, antibodies that react with
human Dll1-, Dll4-, Jagged1- or Jagged2-transfected
CHO cells, but not with untransfected CHO cells, were
screened by flow cytometry. Each mAb was cloned by
limiting dilution.
Balb/c mice were immunized by intraperitoneal injec-
tion of human Notch1-Fc, Notch2-Fc or Notch3-Fc
fusion protein (R&D Systems), or Notch4-transfected
CHO cells three times at seven-day intervals. The hybri-
doma cells were prepared as described above, and anti-
bodies that react with human Notch1-, Notch2-,
Notch3- or Notch4-transfected CHO cells, but not with
untransfected CHO cells, were screened and cloned. All
these mAbs were purified from ascites produced in pri-
stan-primed ICR nude mice by the caprylic acid and
ammonium sulfate precipitation method [12] and
labeled with biotin for flow cytometric analysis.
Other antibodies
Generation and characterization of hamster IgG mAbs
specific for mouse Notch1 (HMN1-12), Notch2
(HMN2-29), Notch3 (HMN3-133), Notch4 (HMN4-14),
Dll1 (HMD1-5), Dll4 (HMD4-2), Jagged1 (HMJ1-29)
and Jagged2 (HMJ2-1) have been described in our
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recent papers [9,13]. Stimulating activity of the anti-
receptor mAbs and blocking activity of the anti-ligand
mAbs have been verified in vitro or in vivo [9,13-20].
Fluorescein isothiocyanate (FITC) -labeled mAbs against
mouse CD11c (HL3), mouse CD61 (2C9.G3), human
CD11c (3.9) and human CD51/CD61 (23C6), PE-labeled
mAb against mouse CD11b (M1/70), and human CD14
(61D3), APC- or PE-conjugated streptavidin were
obtained from eBioscience. FITC-labeled mAb against
mouse F4/80 (CI:A3-1) was from CALTAG (Carlsbad,
CA, USA). Abs specific for cleaved-Notch1 (Val1744)
and Notch2 intracellular domain (411801) were pur-
chased from Cell Signaling (Beverly, MA, USA) and
R&D Systems, respectively. Ab against TATA binding
protein (TBP, ab63766) was from Abcam (Cambridge,
MA, USA).
Cell culture
Murine femoral BM cells from C57BL/6 mice were cul-
tured with 50 ng/ml recombinant mouse (rm) M-CSF
(Wako Chemicals, Osaka, Japan) in alpha-MEM media
(GIBCO, Grand Island, NY, USA) containing 10% fetal
bovine serum (FBS; JRH Bioscience, Lenexa, KS, USA)
for 72 hours. Then, adherent cells were used as osteo-
clast precursors (> 90% CD11b+; Day 0). These cells
(1 × 105 cells/ml) were cultured in the presence of
20 ng/ml rmM-CSF and 100 ng/ml recombinant human
(rh) RANKL (Wako Chemicals). On Day 5, cultures
were fixed with 3.7% formaldehyde and osteoclasts were
characterized by staining for TRAP activity (TRAP stain-
ing kit, Primary Cell Co., Hokkaido, Japan). TRAP-posi-
tive multinucleated cells (MNCs) were observed under a
microscope and counted as osteoclasts. The numbers of
osteoclasts were analyzed statistically by unpaired Stu-
dent’s t test.
Peripheral blood mononuclear cells were prepared
from heparinized blood, obtained from healthy indivi-
duals with informed consent, by Ficoll-Hypaque density
gradient centrifugation. Peripheral blood mononuclear
cells were suspended in alpha-MEM media supplemen-
ted with 10% FBS and cultured for one hour in a flask.
Nonadherent cells were then removed by washing the
flask twice with phosphate-buffered saline (PBS). Adher-
ent cells (> 92% CD14+) were used as osteoclast precur-
sors (PBmono). These cells were further cultured in
alpha-MEM media supplemented with 10% FBS in the
presence of 50 ng/ml rhM-CSF (HumanZyme, Chicago,
IL, USA) for 72 hours (Day 0). Then, cells (5 × 105
cells/ml) were cultured in the presence of 20 ng/ml
rhM-CSF and 100 ng/ml rhRANKL (Wako Chemicals).
On Day 5, osteoclasts were characterized by staining for
TRAP activity. The numbers of osteoclasts were counted
and analyzed statistically by unpaired Student’s t test.
Flow cytometry
Multi-color staining was conducted using combinations of
the indicated mAbs. Briefly, adherent cells in the culture
plate were gently washed with PBS and were detached
with 0.05% Trypsin-EDTA solution (Sigma, St Louis, MO,
USA) at 37°C for five minutes. It was difficult to detach
intact osteoclasts but a part of the osteoclasts could be
analyzed by flow cytometry on Day 5. Cells were first incu-
bated with Fc Block for mice or Fc(gamma)R-Binding
Inhibitor for human, and then with an optimal dilution of
biotinylated mAbs. After washing with 2% FBS in PBS, the
cells were incubated with FITC- or PE-labeled mAbs or
streptavidin, and also stained with 7-amino-actinomycin D
(BD Pharmingen, San Jose, CA, USA) to exclude dead
cells. After washing, the cells were analyzed on FACScan
or FACScaliber (BD Bioscience) and analyzed with Cell-
Quest (BD Bioscience).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated using STAT60 (Tel-Test, Friend-
wood, TX, USA) and was reverse transcribed to comple-
mentary DNA with oligo-dT and SuperScript RT
(Invitrogen, Carlsbad, CA, USA). PCR consisted of 35
cycles of 45 seconds at 94°C, 1 minute at 58°C and 1 min-
ute at 72°C. The primers were as follows: mouse Dll1
sense, 5’-ACCTTCTTTCGCGTATGCCTCAAG-3’ and
mouse Dll1 anti-sense, 5’-AGAGTCTGTATGGAGG
GCTTC-3’; mouse Dll4 sense, 5’-CGAGAGCAGG-
GAAGCCATGA-3’ and mouse Dll4 anti-sense 5’-CCT
GCCTTATACCTCTGTGG-3’; mouse Jagged1 sense, 5’-
ATTCGATCTACATAGCCTGTGAG-3’ and mouse
Jagged1 anti-sense 5’-CTATACGATGTATTCCATC
CGGT-3’; mouse Jagged2 sense, 5’-TGTCAGCCACG-
GAGCAGTCATT-3’ and mouse Jagged2 anti-sense 5’-
TCTCACGTTCTTTCCTGCGCTT-3’; mouse beta-actin
sense, 5’-GTGGGCCGCTCTAGGCACCAA-3’ and
mouse beta-actin anti-sense 5’-CTCTTTGATGTCACG-
CACGCACGATTTC-3’; human Dll1 sense, 5’-AGACG-
GAGACCATGAACAACCT-3’ and human Dll1 anti-
sense, 5’-CGTGGAAGTCCGCCTTCTT-3’; human Dll4
sense, 5’-TCAGCAAGATCGCCATCCA-3’ and human
Dll4 anti-sense 5’AGGGTGCTGGTTTGCTCATC-3’;
human Jagged1 sense, 5’-GAGGCCGCCTCTCT-
GAACTCT-3’ and human Jagged1 anti-sense 5’-
CGATCTTGTTAGTAAACGTGATGGA-3’; human
Jagged2 sense, 5’-AATGGAGTATTCTCGGATAGTT
GCTATT-3’ and human Jagged2 anti-sense 5’-GCA-
CAACCTCTGGTAACAAACG-3’; human beta-actin
sense, 5’-ATCTGGCACCACACCTTCTACAATGAGCT
GCG-3’ and human beta-actin anti-sense 5’-CGTCA-
TACTCCTGCTTGCTGATCCACATCTGC-3’; mouse
Hes-1 sense, 5’-CCGGTCTACACCAGCAACAGT-3’ and
mouse Hes-1 anti-sense 5’-CACATGGAGTCCGAAGT-
GAGC-3’; human Hes-1 sense, 5’-TCAACACGACACC
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GGATAAA-3’ and human Hes-1 anti-sense 5’-
TCAGCTGGCTCAGACTTTCA-3’. PCR products were
separated by electrophoresis on 2.0% agarose gel with
0.5 μg/ml ethidium bromide and detected by UV.
Immunoblotting
Cells were lysed in SDS sample buffer (62.5 mM Tris-
HCl, pH 6.8, 2% SDS, 20% sucrose, 0.02% pyronin G) and
boiled. Samples were subjected to SDS polyacrylamide
gel electrophoresis and transferred to a PVDF membrane.
These membranes were incubated with diluted primary
Abs in 5% Tris buffered saline/Tween 20 (BSA TBS/T)
(10 mM Tris-HCl. pH 7.6, 50 mM NaCl, 0.1% Tween 20)
overnight at 4°C. After washing with TBS/T, membranes
were incubated with a horseradish peroxidase-conjugated
secondary Ab. The immunoreactive proteins were visua-
lized using ECL Plus (GE Healthcare, Chalfont St Giles,
Buckinghamshire, UK).
Animal model of arthritis
Experimental arthritis was induced by passive transfer of
serum from arthritic K/BxN mice, which spontaneously
develop arthritis resembling RA [21]. These mice were
kindly provided by Drs. C. Benoist and D. Mathis (Harvard
Medical School, Boston, MA, USA). Preliminary experi-
ments showed that injection of 100 μl of pooled serum
into the peritoneal cavity on Day 0 and Day 2 induced
arthritis consistently in C57BL/6 mice. Mice with arthritis
were treated by intraperitoneal injection of 0.25 mg of
anti-mouse Dll1 mAb (HMD1-5) or control hamster IgG
(eBioscience) twice a week for two weeks. Treatment was
begun on Day 3. Arthritis in each limb of arthritic mice
was assessed clinically by visual scoring from 1 to 4: 0, no
swelling; 1, detectable swelling in one joint; 2, non-severe
swelling in two or more joints; 3, severe swelling in two or
more joints; and 4, severe swelling in two or more joints
including digital swelling. The maximal score for an indivi-
dual animal was 16. Arthritis scores were analyzed statisti-
cally by Student’s t test.
In histological examination, hindpaws were obtained
and fixed in 10% buffered formalin, decalcified in 10%
EDTA, and embedded in paraffin. Sections (4 μm) were
stained with hematoxylin and eosin for histologic exami-
nation. All procedures met institutional regulations for
animal experiments.
Immunohistochemistry
Paraffin-fixed tissue sections of hindpaws were deparaffi-
nized, pretreated in Liberate Antibody Binding Solution
(Polysciences, Inc., Warrington, PA, USA) for five minutes,
and incubated with 4 μg/ml of anti-TRAP Ab (K-17; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). They
were then incubated with biotinylated Ab against goat
immunoglobulins (DAKO Cytomation, Glostrup, Den-
mark), and ABC reagent (VectaStain Elite ABC kit; Vector
Laboratories, Burlingame, CA, USA) was used for
detection. Color was developed with diaminobenzidine,
whereas the sections were counterstained with hematoxy-
lin. Diaminobenzidine-positive MNCs in the metatarsal
joints were enumerated by observers in a blind manner to
calculate the TRAP-positive osteoclasts per bone surface.
The numbers of TRAP-positive osteoclasts were analyzed
statistically by Student’s t test.
Ovariectomy-induced bone loss
Eight-week-old female C57BL/6 mice were either sham-
operated or ovariectomized (OVX) under anesthesia. 0.25
mg of anti-mouse Dll1 mAb (HMD1-5), anti-mouse
Jagged1 mAb (HMJ1-29) or control hamster IgG was
administered intraperitoneally twice a week for four
weeks. At the end of the experiments, right and left
femora were removed and fixed in 70% ethanol. The
femoral bone was examined radiographically using quan-
titative computed tomography (CT) (LCT-200; LaTheta,
Aloka, Tokyo, Japan) according to the manufacturer’s
instruction. CT scanning was performed at 96 μm inter-
vals and 10 slices of trabecular bone were analyzed. His-
tomorphometric parameters for osteoclastogenesis were
analyzed by staining of femoral bone sections with anti-
TRAP Ab as mentioned above. Parameters obtained from
microCT and histomorphometrical analysis were statisti-
cally analyzed by Student’s t test. All procedures met
institutional guidelines for animal experiments.
Results
Expression of Notch receptors and ligands during
osteoclastogenesis from mouse BM
Mouse BM cells cultured with rmM-CSF for 72 hours
were used as osteoclast precursors (Day 0). Flow cyto-
metric analysis showed CD11b was expressed on more
than 90% of cells during osteoclastogenesis induced with
rmM-CSF and rhRANKL. Among these CD11b+ osteo-
clast precursors, F4/80+ cells differentiate into osteoclasts
although the terminally differentiated osteoclasts do not
express F4/80 [5,22]. As shown in Figure 1a, a substantial
part of the CD11b+ cells expressed F4/80 during osteoclas-
togenesis. Then, the expression of Notch receptors and
ligands on CD11b+F4/80+ cells were examined. CD11b
+F4/80+ osteoclast precursors expressed Notch2, Notch3
and Jagged2 on Day 0 (Figure 1b). Stimulation with rmM-
CSF and rhRANKL induced Notch1, Dll1 and Jagged1
expression on Day 3 (Figure 1b). A part of these cells
differentiated into CD11b+CD61+ osteoclasts on Day 5
(Figure 1a). On Day 5, expression of Notch1, Dll1 and
Jagged1 declined on CD11b+F4/80+ cells, and on CD11b
+CD61+ osteoclasts (Figure 1b). CD11b+F4/80- cells do
not differentiate into osteoclasts but could potentially sti-
mulate Notch receptors on CD11b+F4/80+ cells. However,
Notch ligands were not expressed on CD11b+F4/80- cells
while Notch2 and Notch3 were expressed on Day 3
Sekine et al. Arthritis Research & Therapy 2012, 14:R45
http://arthritis-research.com/content/14/2/R45
Page 4 of 14
(Figure 1b), as well as on Day 0 and Day 5 (data not
shown). RT-PCR analysis during osteoclastogenesis also
showed an increase of Dll1 and Jagged1 messenger RNA
levels in total cells on Day 3, although they were still
detected on Day 5 (Figure 1c). BM derived-macrophages,
which were derived from BM cells by culturing with
rmM-CSF alone, showed Notch receptor and ligand
expression similar to osteoclast precursors at Day 0
(Figure 1b). In contrast, BM derived-dendritic cells
expressed only Notch2 (Figure 1b).
Dll1 enhances but Jagged1 suppresses osteoclastogenesis
from mouse BM
Since both Notch receptors and ligands were expressed on
CD11b+F4/80+ osteoclast precursors during osteoclasto-
genesis, we examined the role of Notch ligands. As shown
in Figure 2a, blocking of Notch signaling by a gamma-
secretase inhibitor, DAPT, significantly inhibited RANKL-
induced osteoclastogenesis. Anti-mouse Dll1 blocking
mAb also markedly inhibited the osteoclastogenesis. Anti-
mouse Dll4 blocking mAb had no effect on osteoclast dif-
ferentiation, consistent with no expression of Dll4 during
osteoclastogenesis. Anti-mouse Jagged1 blocking mAb sig-
nificantly enhanced osteoclastogenesis. Anti-mouse
Jagged2 blocking mAb slightly enhanced osteoclastogen-
esis but not significantly. Blocking of Notch signaling with
anti-mouse Dll1 or anti-mouse Jagged1 mAb, as well as
DAPT, was shown by the inhibition of Hes-1 expression
(Figure 2b). Combinational blockade of Dll1 with either
Dll4, Jagged1 or Jagged2 also markedly decreased the
osteoclastogenesis (Figure 2a). These results indicate that
Dll1 plays a predominant role among Notch ligands in
supporting osteoclast differentiation from mouse BM.
To confirm the effect of each Notch ligand on osteo-
clastogenesis, Notch receptors on osteoclast precursors
were activated by Fc fusion protein of each Notch ligand.
Accordingly, mouse Dll1-Fc significantly enhanced the
osteoclastogenesis, whereas mouse Jagged1-Fc sup-
pressed it (Figure 2c). Moreover, Dll1-deficient BM cells
showed a greatly reduced osteoclastogenesis as compared
with control cells (Figure 2d). Collectively, these results
indicate that Dll1 enhances but Jagged1 suppresses
osteoclastogenesis.
Notch2 promotes but Notch1 suppresses
osteoclastogenesis from mouse BM
To investigate if the activation of each Notch receptor
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Figure 1 Expression of Notch receptors and ligands during osteoclastogenesis from mouse BM. BM cells cultured with rmM-CSF for
72 hours were used as osteoclast precursors (Day 0). These cells were further cultured with rmM-CSF and rhRANKL to induce osteoclasts.
(a) CD11b+F4/80+ osteoclast precursors and CD11b+CD61+ osteoclasts were analyzed on days 0, 3 and 5. Percentages from three independent
experiments are indicated. (b) Expression of Notch receptors and ligands on CD11b+F4/80+ osteoclast precursors was analyzed by flow
cytometry on days 0, 3 and 5. Expression on CD11b+F4/80- cells on Day 3 is also represented. CD11b+CD61+ osteoclasts were analyzed on Day
5. For comparison, BM cells were cultured with rmM-CSF alone for eight days and CD11b+F4/80+ cells were analyzed as BM-derived
macrophages (BMMø), or with rmGM-CSF for eight days with LPS stimulation for the last 17 hours and CD11c+ cells were analyzed as BM-
derived dendritic cells (BMDC). Filled histograms indicate the control hamster IgG. Open histograms indicate the Notch receptors or ligands.
(c) Messenger RNA levels of Notch ligands were measured by RT-PCR on days 0, 3 and 5.
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Figure 2 Effects of Notch ligand blockade and Notch receptor stimulation on osteoclastogenesis from mouse BM. (a) Osteoclasts were
induced from mouse BM as described in Figure 1. DAPT (10 μM), DMSO as a control, 20 μg/ml of the indicated mAb (D1, HMD1-5; D4, HMD4-2;
J1, HMJ1-29; J2, HMJ2-1), or control hamster IgG (Ham) was added on Day 0 and Day 3. (b) Osteoclasts were induced as described in (a) and
mRNA levels of Hes-1 and beta-actin were determined by RT-PCR on Day 3. (c and e) Osteoclast precursors were pre-incubated with Fc Block
and then differentiated on the plate immobilized with 10 μg/ml of the indicated Fc chimera or control human IgG-Fc fragment (hIgG-Fc) (c), or
with 5 μg/ml of the indicated mAb (N1, HMN1-12; N2, HMN2-29; N3, HMN3-133; N4, HMN4-14) or Ham (e). (d) BM cells from Dll1-conditional
knockout or littermate control mice were differentiated into osteoclasts. ***, P < 0.001. (a, c-e) Osteoclasts were stained for TRAP. Representative
stainings are shown. Original magnification: × 100. Data are indicated as the mean TRAP-positive MNCs per culture well ± SD of triplicated wells.
#, P < 0.001 versus DMSO control. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus Ham or hIgG-Fc control. Similar results were obtained in three
independent experiments.
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osteoclast precursors from mouse BM were differen-
tiated on the culture plate immobilized with mAb
against each Notch receptor. Osteoclastogenesis was
enhanced by anti-Notch2 agonistic mAb while it was
suppressed by anti-Notch1 agonistic mAb (Figure 2e).
The activation of Notch3 did not show any effect,
though it was expressed during osteoclastogenesis (Fig-
ures 1b and 2e). Notch4 was not expressed during
osteoclastogenesis and anti-mouse Notch4 mAb had no
effect on osteoclast differentiation (Figures 1b and 2e).
These results indicate that Notch2 enhances, but
Notch1 suppresses, osteoclastogenesis.
Expression of Notch receptors and ligands during
osteoclastogenesis from human PBmono
To study the role of Notch receptors and ligands in
human osteoclastogenesis, we established mAbs specific
for human Notch1, Notch2, Notch3, Notch4, Dll1, Dll4,
Jagged1 and Jagged2 (Figure 3a, b). Then, the expression
of Notch receptors and ligands during osteoclast differ-
entiation from human PBmono were determined by
flow cytometry. More than 92% of cells expressed CD14
during osteoclastogenesis induced with rhM-CSF and
rhRANKL, which were analyzed as osteoclast precursors.
5 to 10% of CD14+ cells expressed CD51/CD61 on
day 3 
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day 0 3 5 
Figure 3 Expression of Notch receptors and ligands during osteoclastogenesis from human PBmono. Reactivity of anti-human Notch
receptor mAbs (a) or anti-human Notch ligand mAbs (b) against CHO transfectants. Open histograms indicate the staining with anti-Notch1
(MHN1-128), anti-Notch2 (MHN2-25), anti-Notch3 (MHN3-21), anti-Notch4 (MHN4-2), anti-Dll1 (MHD1-314), anti-Dll4 (MHD4-46), anti-Jagged1
(MHJ1-152) or anti-Jagged2 (MHJ2-473) mAb. Filled histograms indicate the staining with control mouse IgG (a-c). (c) PBmono cultured with
rhM-CSF for 72 hours were used as osteoclast precursors (Day 0). These cells were further cultured with rhM-CSF and rhRANKL to induce
osteoclasts. CD14+ cells were analyzed by flow cytometry on days 0, 3 and 5. CD51/CD61+CD14+ osteoclasts were analyzed on Day 5. For
comparison, PBmono were cultured with rhM-CSF alone for eight days and CD14+ cells were analyzed as macrophages (Mø), or with rhGM-CSF
and rhIL-4 for seven days with LPS stimulation for the last 48 hours and CD11c+ cells were analyzed as dendritic cells (DC). Open histograms
indicate the staining with MHN1-128 (Notch1), MHN2-25 (Notch2), MHN3-21 (Notch3), MHN4-2 (Notch4), MHD1-314 (Dll1), MHD4-46 (Dll4), MHJ1-
152 (Jagged1), or MHJ2-473 (Jagged2). (d) Osteoclasts were induced as described in (c). Messenger RNA levels of Notch ligands were measured
by RT-PCR on days 0, 3 and 5.
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Day 5, which were analyzed as osteoclasts. While
Notch1 and Notch2 were expressed on PBmono,
Notch3 expression was induced by rhM-CSF stimulation
for 72 hours (Figure 3c, Day 0). The expression of
Notch1, Notch2 and Notch3 was maintained during
osteoclastogenesis, including CD14+CD51/CD61+ osteo-
clasts on Day 5 although the expression levels were
higher on Day 0 (Figure 3c). Similarly to the mouse BM,
induction of Dll1 expression on CD14+ osteoclast pre-
cursors was observed on Day 3 of RANKL stimulation,
albeit at a low level. Meanwhile, Jagged1 was constitu-
tively expressed (Figure 3c). RT-PCR analysis during
osteoclastogenesis also showed the increase of Dll1 at
messenger RNA level on Day 3 in total cells (Figure 3d).
Monocyte-derived macrophages, which were induced
with rhM-CSF alone, expressed only Notch2 and
Jagged1 (Figure 3c). Monocyte-derived dendritic cells
expressed Notch1, Notch2 and Jagged1 as did PBmono
(Figure 3c).
Dll1 enhances but Jagged1 suppresses osteoclastogenesis
from human PBmono
To determine the role of Notch ligands in osteoclast dif-
ferentiation from human PBmono, Notch ligands were
blocked by mAbs specific for human Dll1, Dll4, Jagged1 or
Jagged2. Similar to the effect on osteoclastogenesis from
mouse BM, DAPT significantly inhibited the differentia-
tion of osteoclasts from human PBmono (Figure 4a).
Blockade of Dll1 also significantly inhibited the differentia-
tion of osteoclasts (Figure 4a). In contrast, blockade of
Jagged1 significantly enhanced the osteoclast differentia-
tion, while blockade of Dll4 or Jagged2 had no significant
effect (Figure 4a). Suppression of Hes-1 expression with
anti-human Dll1 or anti-human Jagged1 mAb, as well as
DAPT, showed the inhibition of Notch signaling (Figure
4b). Conversely, stimulation with immobilized human
Dll1-Fc enhanced the osteoclastogenesis, while human
Jagged1-Fc suppressed it (Figure 4c). Decreasing the dose
of RANKL clearly showed the enhancement of osteoclas-
togenesis by blockade of Jagged1, as well as by stimulation
with human Dll1-Fc (Figure 4d). These results indicate
that Dll1 positively regulates the osteoclastogenesis from
PBmono but Jagged1 regulates it negatively.
Notch2 promotes but Notch1 suppresses
osteoclastogenesis from human PBmono
Then, we determined the effect of each Notch receptor
activation on the differentiation of osteoclasts from
human PBmono. Similarly to the mouse BM (Figure 2e),
osteoclastogenesis was significantly enhanced by stimula-
tion with anti-Notch2 mAb but suppressed by anti-
Notch1 mAb, while anti-Notch3 or anti-Notch4 mAb
had no effect (Figure 4e). These results suggest that
Notch2/Dll1 interaction promotes the differentiation of
osteoclasts while Notch1/Jagged1 interaction suppresses
it in both mice and humans.
Preferential activation of Notch2 or Notch1 signaling by
Dll1 or Jagged1 stimulation
To address whether Notch1 preferentially interacts with
Jagged1 and Notch2 preferentially interacts with Dll1, acti-
vation of Notch1 and Notch2 by Dll1-Fc or Jagged1-Fc sti-
mulation during osteoclastogenesis was examined by
immunoblotting of Notch1 and Notch2 intracellular
domains (ICDs). As shown in Figure 5, Notch1 ICD was
preferentially induced by the stimulation with Jagged1-Fc.
On the other hand, Notch2 ICD was preferentially
induced by the stimulation with Dll1-Fc. These results
indicate the preferential interactions of Notch1/Jagged1
and Notch2/Dll1 during osteoclastogenesis.
Blockade of Dll1 ameliorates arthritis and reduces
osteoclasts in the affected joints
Osteoclasts are known to play a pivotal role in the patho-
genesis of bone erosion in RA, and our data indicated that
osteoclastogenesis was dominantly supported by Dll1
among Notch ligands. In order to explore the role of Dll1
at the effecter phase of arthritis, K/BxN serum-induced
arthritic mice, a mouse model for RA, were therapeutically
treated with anti-mouse Dll1 mAb. K/BxN T cell recep-
tor-transgenic mice produce high-titer arthritogenic auto-
antibody and spontaneously develop erosive polyarthritis
resembling RA [21]. Passive transfer of serum containing
arthritogenic autoantibody from K/BxN mice into normal
mice also induces arthritis [23,24]. This serum-induced
arthritis model makes it possible to focus on addressing
the effecter phase of arthritis so that it is induced without
the induction phase, including complicated immune
responses. Actually, arthritis score and hematoxylin and
eosin staining demonstrated that anti-mouse Dll1 mAb
treatment ameliorated K/BxN serum-induced arthritis as
compared to control hamster IgG treatment (Figure 6a).
These arthritic mice developed joint deformity resembling
RA, which can be determined visually. The incidence of
joint deformity was decreased by the Dll1 blockade to
7.14% as compared to 57.1% of control (data not shown).
TRAP immunohistochemistry showed that TRAP+ multi-
nucleated osteoclasts in the affected joints were signifi-
cantly reduced by the Dll1 blockade (Figure 6b).
Blockade of Dll1 suppresses OVX-induced bone loss
The reduction of osteoclasts in the affected joints of
arthritic mice by the Dll1 blockade might be a result from
the reduced inflammation. To investigate the direct effect
of Dll1 blockade on osteoclastogenesis in vivo, the effect of
anti-mouse Dll1 mAb on OVX-induced bone loss, a
mouse model of osteoporosis, was evaluated. Trabecular
and cortical bone mineral density (BMD) were markedly
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reduced in OVX mice. The anti-mouse Dll1 mAb treat-
ment significantly increased trabecular BMD of OVX mice
as compared to the control hamster IgG treatment
although it had no effect on sham-operated mice (Figure
7). Meanwhile, the Dll1 blockade was not affected on cor-
tical BMD of OVX and sham-operated mice as compared
to the control hamster IgG treatment (Figure 7). OVX-
induced reduction of trabecular bone area, as well as
trabecular bone volume/tissue volume (BV/TV), was also
significantly prevented by the Dll1 blockade while OVX
had no effect on cortical bone area (Figure 7). In addition,
the Dll1 blockade protected against OVX-induced reduc-
tion of polar moment of inertia, a parameter of bone
strength that described the resistance to twisting (Figure
7). Histomorphometric parameters (osteoclast number/























































































































































































































Figure 4 Effects of Notch ligand blockade and Notch receptor stimulation on osteoclastogenesis from human PBmono. (a) Osteoclasts
were differentiated from human PBmono as described in Figure 3. DAPT (10 μM), DMSO as a control, 20 μg/ml of the indicated mAb (hD1,
MHD1-314; hD4, MHD4-46; hJ1, MHJ1-152; hJ2, MHJ2-473), or control mouse IgG (mIg) was added on Day 0 and Day 3. (b) Osteoclasts were
induced as described in (a) and mRNA levels of Hes1 and beta-actin were determined by RT-PCR. (c and e) Osteoclast precursors were pre-
incubated with Fc(gamma)R-binding inhibitor and then differentiated on the culture plate immobilized with 10 μg/ml of the indicated Fc
chimera or control human IgG-Fc fragment (hIgG-Fc) (c), or with 5 μg/ml of the indicated mAb (hN1, MHN1-128; hN2, MHN2-25; hN3, MHN3-21;
hN4, MHN4-2) or mIg (e). (d) Osteoclasts were differentiated as described in (a) or (c) in the presence of a low dose of rhRANKL (12.5 ng/ml). (a,
c-e) Osteoclasts were stained for TRAP. Representative stainings are shown (a, c and e). Original magnification: ×100. Data are indicated as the
mean TRAP-positive MNCs per culture well ± SD of triplicated wells..#, P < 0.001; versus DMSO control. *, P < 0.05; **, P < 0.01; ***, P < 0.001
versus mIg or hIgG-Fc control. Similar results were obtained in three independent experiments.
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revealed suppression of osteoclastogenesis by the Dll1
blockade in OVX mice (Figure 7). These data indicate that
blockade of Dll1 improves OVX-induced bone loss. Nota-
bly, the Jagged1 blockade did not show significant effect
on these parameters of OVX and sham-operated mice
(Figure 7).
Discussion
In this study, we demonstrated that mouse osteoclast
precursors expressed multiple Notch receptors and
ligands during osteoclastogenesis, but Notch2/Dll1 axis
enhanced and Notch1/Jagged1 axis suppressed osteo-
clastogenesis selectively. A similar regulation of osteo-
clastogenesis by Notch2/Dll1 and Notch1/Jagged1 axes
was also demonstrated in humans. Finally, we showed
that blockade of Dll1 could suppress osteoclastogenesis
in the affected joints in a murine arthritis model.
The inhibition of osteoclastogenesis by Dll1 blockade
and the enhancement by stimulation with Dll1-Fc and
anti-Notch2 mAb suggest that Dll1 promotes osteoclas-
togenesis via Notch2. On the other hand, the enhance-
ment of osteoclastogenesis by Jagged1 blockade and the
inhibition by stimulation with Jagged1-Fc and anti-
Notch1 mAb suggest that Jagged1 suppresses osteoclas-
togenesis via Notch1. The preferential induction of
Notch1 ICD by Jagged1-Fc stimulation and that of
Notch2 ICD by Dll1-Fc stimulation supported this
notion. Although we could not directly indicate the pre-
ferential Dll1/Notch2 and Jagged1/Notch1 interactions
due to a lack of appropriate blocking mAbs against
Notch1 and Notch2, such a preferential Notch2/Dll1
interaction also plays a key role in the development of
marginal zone B cells in the spleen [25] and a
preferential Notch1/Jagged1 interaction has been impli-
cated in the maintenance of hematopoietic stem cells in
the BM [26,27]. It has been known that interaction of
Notch receptors with Dll versus Jagged ligands is
affected by glycosylation of Notch extracellular domain
by Fringe [28,29]. Therefore, a differential modification
of Notch1 and Notch2 on osteoclast precursors by
Fringe or a differential modification of Notch1 and
Notch2 interactions with Jagged1 and Dll1 by Fringe
might be responsible for the preferential Notch2/Dll1
and Notch1/Jagged1 interactions. Further studies are
needed to address these possibilities.
The enhancement of osteoclastogenesis by stimulation
with anti-Notch2 mAb and the suppression by anti-
Notch1 mAb suggest a differential signaling via Notch1
versus Notch2. The inhibition of osteoclastogenesis by
blockade of net Notch signaling by DAPT implies that
the promotion via Notch2 is dominant over the suppres-
sion via Notch1 during osteoclastogenesis. The pro-
osteoclastogenic function of Notch2 is consistent with a
previous report demonstrating that silencing Notch2
with small hairpin RNA suppressed osteoclastogenesis
and overexpression of Notch2 intracellular domain
enhanced it [4]. The anti-osteoclastogenic function of
Notch1 is also consistent with a previous report demon-
strating that deletion of Notch1 in murine myeloid cells
enhanced osteoclastogenesis and bone resorption [3].
Notch2 has been shown to act in conjunction with
nuclear factor-kappaB, possibly by regulating the nuclear
factor of activated T cells (NFAT)-c1 promoter during
the terminal differentiation of osteoclasts [4]. In contrast,
Jagged1-mediated Notch1 signaling could not cooperate
with nuclear factor-kappaB but was likely to inhibit pro-
liferation of osteoclast precursors [3].
Blockade of Dll1 suppressed the osteoclastogenesis not
only in vitro but also in a murine arthritis model. Preven-
tion of OVX-induced trabecular bone loss by the Dll1
blockade supported the effect in vivo. Notably, blockade of
Dll1, as well as Jagged1, did not affect the parameters of
bone strength and structure in the absence of any stimula-
tion as shown in sham-operated mice. A high expression
of Dll1 and Jagged1 as well as Notch1, Notch2 and
Notch3 has been demonstrated in the synovium of RA
patients [30,31]. We previously demonstrated that Dll1
was expressed on a part of the macrophage population
and that inflammatory cytokines, such as tumor nuclear
factor-alpha or interferon-gamma, induced the expression
of Dll1 on macrophages [9]. Thus, Dll1 blockade may be a
novel strategy to prevent bone erosion in RA patients by
suppressing the inflammation-associated osteoclastogen-
esis. In addition, Dll1 has also been implicated in the
development of pathogenic Th1 effector cells [32,33],
while Jagged1 has been implicated in the development of






















Figure 5 Preferential activation of Notch2 or Notch1 by the
stimulation with Dll1-Fc or Jagged1-Fc. Osteoclasts were
differentiated from mouse BM as described in Figure 2c. ICDs of
Notch1 and Notch2 on day 1 were analyzed by Western
immunoblotting. TBP was used as a loading control. N1, Notch1; N2,
Notch2. Similar results were obtained in three independent
experiments.
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Figure 6 Amelioration of arthritis and reduction of osteoclast numbers in the affected joints by blockade of Dll1. Mice with K/BxN
serum-induced arthritis were treated with control hamster IgG (Ham) or HMD1-5 (D1). (a) Severity of arthritis was assessed by an arthritis score.
Mean score ± SEM is shown (n = 7 mice per group). *, P < 0.05; **, P < 0.01 versus control hamster IgG. Representative hematoxylin and eosin
staining of joints on Day 13 is shown. Original magnification ×100. Similar results were obtained in two independent experiments. (b) TRAP
immunohistochemistry of joints. Number of TRAP+ MNCs in joints on Day 13 was measured. Shown are the mean number of TRAP+ MNCs
relative to bone surface ± SEM of 10 joints from 5 mice per group. ***, P < 0.001 versus control hamster IgG. Representative staining is shown.
Original magnification; ×100, ×400.
Sekine et al. Arthritis Research & Therapy 2012, 14:R45
http://arthritis-research.com/content/14/2/R45
Page 11 of 14
previously demonstrated that Dll1 blockade ameliorated
experimental autoimmune encephalomyelitis while
Jagged1 blockade exacerbated it [14]. Moreover, we
recently demonstrated that Jgged1 blockade exacerbated
collagen-induced arthritis [36]. Therefore, the blockade of
Dll1/Notch2 axis and the enhancement of Jagged1/Notch1
axis may be beneficial for the treatment of RA through
multiple mechanisms.
Conclusions
We demonstrate that Dll1 promotes osteoclastogenesis
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Figure 7 Effect of Dll1 blockade on OVX-induced bone loss in mice. OVX or sham-operated mice were treated with control hamster IgG
(Ham), HMD1-5 (D1) or HMJ1-29 (J1). Trabecular and cortical BMD, trabecular and cortical bone area, bone volume per tissue volume (BV/TV),
polar moment of inertia in the distal femur, osteoclast number/bone perimeter, and osteoclast surface/bone surface were evaluated four weeks
after sham operation or OVX. Shown are the mean value ± SEM of 10 femora from 5 mice per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Sekine et al. Arthritis Research & Therapy 2012, 14:R45
http://arthritis-research.com/content/14/2/R45
Page 12 of 14
via Notch1 in both mice and humans. Osteoclastogen-
esis is suppressed by inhibition of Notch signaling with
a gamma-secretase inhibitor, implying that Notch2/Dll1-
mediated enhancement is dominant. Notably, blockade
of Dll1 with anti-Dll1 mAb in RA model mice amelio-
rates arthritis and reduces the number of osteoclasts in
the affected joints. Prevention of OVX-induced trabecu-
lar bone loss by the Dll1 blockade supported the effect
in osteoclastogenesis. We, therefore, propose that the
differential regulation of osteoclastogenesis by Notch2/
Dll1 and Notch1/Jagged1 axes could be a novel target
for the treatment of RA to prevent bone erosion.
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